Literature DB >> 25774375

The use (or rather the non-use) of cost-effectiveness data in priority setting decisions - are we underestimating the barriers to using health economics in real world priority setting decisions?: Comment on "Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden".

Sandra T Erntoft1.   

Abstract

After having practicing and researching health economics for nearly 15 years now, it has become clear to me that the use of cost-effectiveness data in priority setting decisions is rather a rare than a common practice. The Eckard et al. article though, describes a wonderful exception to this rule and a very good example of how it can be used when the conditions are right. However, do we fully understand what these conditions are? In this commentary article I will address some of the institutional and cultural conditions that need to be fulfilled in order for cost-effectiveness data to actually be used in priority setting decisions.

Entities:  

Keywords:  Cost-effectiveness; Health Policy; Priority Setting

Year:  2015        PMID: 25774375      PMCID: PMC4357985          DOI: 10.15171/ijhpm.2015.28

Source DB:  PubMed          Journal:  Int J Health Policy Manag        ISSN: 2322-5939


  9 in total

Review 1.  Application of pharmacoeconomics to formulary decision making in managed care organizations.

Authors:  Dong-Churl Suh; Ijeoma R N Okpara; Wendy B Agnese; Michael Toscani
Journal:  Am J Manag Care       Date:  2002-02       Impact factor: 2.229

2.  Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.

Authors:  Norman Daniels; James Sabin
Journal:  Philos Public Aff       Date:  1997

3.  A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey.

Authors:  Hans-Martin Späth; Marie Charavel; Magali Morelle; Marie-Odile Carrere
Journal:  Pharm World Sci       Date:  2003-12

4.  Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.

Authors:  Anders Anell
Journal:  Eur J Health Econ       Date:  2004-02

Review 5.  Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels.

Authors:  Marieke E van Velden; Johan L Severens; Annoesjka Novak
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Decision-making in priority setting for medicines--a review of empirical studies.

Authors:  Lauri Vuorenkoski; Hanna Toiviainen; Elina Hemminki
Journal:  Health Policy       Date:  2007-10-22       Impact factor: 2.980

Review 7.  A systematic review of the use of economic evaluation in local decision-making.

Authors:  Oya Eddama; Joanna Coast
Journal:  Health Policy       Date:  2008-01-14       Impact factor: 2.980

8.  The use of economic evaluations in NHS decision-making: a review and empirical investigation.

Authors:  I Williams; S McIver; D Moore; S Bryan
Journal:  Health Technol Assess       Date:  2008-04       Impact factor: 4.014

9.  Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden.

Authors:  Nathalie Eckard; Magnus Janzon; Lars-Åke Levin
Journal:  Int J Health Policy Manag       Date:  2014-10-27
  9 in total
  1 in total

1.  Including Both Costs and Effects--The Challenge of Using Cost-Effectiveness Data in National-Level Policy-Making: A Response to Recent Commentaries.

Authors:  Nathalie Eckard; Magnus Janzon; Lars-Åke Levin
Journal:  Int J Health Policy Manag       Date:  2015-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.